The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Immuno-Oncology 2022 | Future directions in lung cancer immunology research
James Reading, PhD, University College London, London, UK, provides an overview of advances in the field of lung cancer immunology. Elucidating the stages of immune recognition of tumors and how the process deteriorates will improve our understanding of cancer pathology. Future findings may additionally lead to non-invasive early detection techniques, which can ultimately lead to improved outcomes in patients. Dr Reading also highlights research in the immune landscape in lung tumors, resulting in enhanced checkpoint inhibition. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
